NCT02446561已完成1 期
A Study of Whether 3 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Bioequivalence as measured by PK parameters
研究概览
简要总结
To determine whether three new oral formulations of a strong pain killer release the drug into the body in a similar pattern as the already marketed reference capsule formulation with or without food
详细描述
Comparisons will be made between three new oral formulations and an existing marketed reference capsule formulation to determine whether the release rates of the products are similar or equivalent in a fed or fasted state. Determination is by measurement of drug concentrations in the blood at serial collection time points pre-dose until 72 hours post-dose, following an administration of a single oral dose. Pharmacokinetics parameters of AUC and Cmax are the primary endpoints
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provide written informed consent.
- •Healthy male or female subjects aged 18 to 55 inclusive.
- •Female subjects of child bearing potential must be willing to use two highly effective methods of contraception throughout the study, one of which must include a barrier method.
- •Female subjects who are post-menopausal (defined as spontaneous amenorrhea for at least a year) or permanently sterilised (e.g. tubal occlusion, hysterectomy, bilateral salpingectomy). These subjects are not required to use any contraception.
- •Male subjects must be willing to use contraception with their partners throughout the study and for 30 days after completion of the study and agree to inform the Investigator if their partner becomes pregnant during this time.
- •Body weight ranging from 55 to 100 kg and a BMI ≥ 18.5 and ≤ 30.
- •Healthy and free of significant abnormal findings as determined by medical history, physical examination, vital signs, laboratory tests and ECG.
- •Willing to eat all the food supplied throughout the study.
- •The subject's primary care physician has confirmed within the last 12 months of first dosing that there is nothing in their medical history that would preclude their enrolment into a clinical study
排除标准
- •Any history of drug or alcohol abuse.
- •Any history of conditions that might interfere with drug absorption, distribution, metabolism or excretion.
- •Use of opioid or opioid antagonist-containing medication in the past 30 days.
- •Any history of frequent nausea or vomiting regardless of etiology.
- •Any history of seizures or symptomatic head trauma.
- •Any history of paralytic ileus, respiratory depression, hypoxia or elevated carbon dioxide levels in the blood.
- •Participation in a clinical drug study during the 90 days preceding the initial dose in this study.
- •Subjects must not participate in both the pilot phase and the definitive phase of the study, or in more than one Cohort.
- •Any significant illness during the 4 weeks preceding entry into this study.
- •Use of any medication including vitamins, herbal and/or mineral supplements during the 7 days preceding the initial dose or during the course of this study (with the exception of the continued use of HRT and contraceptives).
- •Refusal to abstain from food 8 hours preceding and 4 hours following study drug administration, to abstain from foods containing poppy seeds 48 hours preceding and entirely during each confinement, and to abstain from caffeine or xanthine containing food or beverages and grapefruit juice within 48 hours before IMP administration and for the duration of study confinement until after the last study PK sample has been taken in each study period.
- •Weekly alcohol intake exceeding the equivalent of 14 units/week for females and 21 units/week for males. (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine).
- •Consumption of alcoholic beverages within 48 hours before study drug administration, and refusal to abstain from alcohol for the duration of the study confinement and for at least 48 hours after the last naltrexone dose in each study period.
- •History of smoking within 45 days of study drug administration and refusal to abstain from smoking during the study.
- •Blood or blood products donated within 90 days prior to study drug administration or any time during the study, except as required by this protocol.
- •Positive results of urine drug screen, alcohol test, pregnancy test, HBsAg, Hepatitis C antibody, or HIV tests.
- •Refusal to allow their primary care physician to be informed of participation in the trial.
- •Failure to satisfy the Investigator of fitness to participate for any other reason.
研究组 & 干预措施
MRXXX
Active Comparator
Active comparator
干预措施: MRXXX (Drug)
MR1XXX
Experimental
MR1XXX
干预措施: MR1XXX (Drug)
MR2XXX
Experimental
MR2XXX
干预措施: MR2XXX (Drug)
MR3XXX
Experimental
MR3XXX
干预措施: MR3XXX (Drug)
结局指标
主要结局
Bioequivalence as measured by PK parameters
时间窗: Up to 72 hours
AUCt, AUCINF, LambdaZ, t1/2Z, Cmax and tmax
次要结局
- Safety and tolerability as measured by adverse events, vital signs, clinical lab results and ECGs.(Up to 7-10 days after last dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of Whether 2 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed MedicationPainNCT02089581Mundipharma Research Limited32
已完成
1 期
A Research Study Looking at New Protein-based Tablets in Healthy Male ParticipantsHealthy VolunteersHigh Blood Cholesterol LevelsType 2 DiabetesNCT05129891Novo Nordisk A/S384
已完成
3 期
Analgesic Effectiveness of Three Different Doses of a New Formulation of Lamaline in a Model of Painful Knee (Gonarthrosis)Knee OsteoarthritisNCT00264225Solvay Pharmaceuticals
终止
3 期
Sciatica Epidural Radiculopathy Experimental New Interventional TherapY Clonidine MicropelletLumbosacral RadiculopathyNCT05614648Sollis Therapeutics, Inc.17
已完成
1 期
Pharmacokinetics and Bioavailability Study of Lasolvan Hard Capsules and Effervescent Tablets in Healthy VolunteersHealthyNCT02036775Boehringer Ingelheim24